Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials. (Q34823275)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25387312%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

title

Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25387312%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1 reference

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25387312%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

12

Joseph Eron

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25387312%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

10

W Garrett Nichols

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25387312%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

11

Robert Liam Cuffe

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25387312%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1

François Raffi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25387312%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

author name string

Anita Rachlis

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25387312%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Cynthia Brinson

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25387312%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Keikawus Arasteh

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25387312%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Miguel Górgolas

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25387312%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Clare Brennan

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25387312%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Keith Pappa

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25387312%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Steve Almond

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25387312%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Catherine Granier

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25387312%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

language of work or name

English

0 references

publication date

1 January 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25387312%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25387312%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

volume

29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25387312%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25387312%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

page(s)

167-174

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25387312%20AND%20SRC:MED&resulttype=core&format=json

Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study

22 February 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4284010

Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4284010

Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4284010

Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4284010

Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4284010

Safety and efficacy of raltegravir in patients with HIV-1 and hepatitis B and/or C virus coinfection

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4284010

Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4284010

Ethnicity, race, and gender. Differences in serious adverse events among participants in an antiretroviral initiation trial: results of CPCRA 058 (FIRST Study).

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4284010

A prospective, 96-week study of the impact of Trizivir, Combivir/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4284010

The eldest of older adults living with HIV: response and adherence to highly active antiretroviral therapy

26 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25387312

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1097/QAD.0000000000000519

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25387312%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25387312%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25387312%20AND%20SRC:MED&resulttype=core&format=json